Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Woodline Partners LP

Woodline Partners LP boosted its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 5.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 396,600 shares of the company’s stock after buying an additional 19,538 shares during the quarter. Woodline Partners LP’s holdings in Disc Medicine were worth $25,144,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IRON. Barclays PLC raised its holdings in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after acquiring an additional 22,202 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Disc Medicine by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after purchasing an additional 2,257 shares during the last quarter. SG Americas Securities LLC raised its stake in Disc Medicine by 66.0% in the 4th quarter. SG Americas Securities LLC now owns 8,076 shares of the company’s stock valued at $512,000 after purchasing an additional 3,212 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after purchasing an additional 593 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in Disc Medicine during the 4th quarter worth $486,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on IRON shares. Stifel Nicolaus increased their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. TD Cowen initiated coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. BMO Capital Markets upped their price target on Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday, May 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $98.80.

Insiders Place Their Bets

In related news, Director Mona Ashiya sold 202,146 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the completion of the sale, the director now directly owns 208,742 shares of the company’s stock, valued at approximately $11,332,603.18. This trade represents a 49.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the transaction, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. The trade was a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 342,833 shares of company stock valued at $18,602,418 over the last quarter. 4.24% of the stock is owned by insiders.

Disc Medicine Price Performance

NASDAQ:IRON opened at $50.08 on Wednesday. The company’s 50-day moving average is $45.97 and its two-hundred day moving average is $55.00. Disc Medicine, Inc. has a 1-year low of $30.65 and a 1-year high of $68.73. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -12.58 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.